Get notified when DMRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Going Concern (removed) — Baseline disclosed substantial doubt about ability to continue as going concern with $10.2M cash; current filing has $540.5M cash and no going-concern language — financial position materially improved following Nov 2025 acquisition and equity raises.
Damora posts -$31.2M net loss (widened 807%) on $23.6M ATM raise and mutCALR trial launch
Filed August 10, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read
Key Changes
-
high
cash now $540.5M, extending runway into H2 2029 and eliminating prior going-concern condition.
MD&A: Liquidity / Notes: Equity Raises verify on EDGAR → -
high
DMR-001 Phase 1/1b trial initiated in essential thrombocythemia and myelofibrosis patients, with first country approval received; two proof-of-concept readouts expected beginning mid-2027, potential Phase 3 start mid-2028.
MD&A: Clinical Programs verify on EDGAR → -
high
Operating loss widened from $3.4M to $35.0M (923%) as R&D expenses surged $24.1M to $25.5M
MD&A: Operating Expenses verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FGBI 10-Q) is open in full — no account needed.
Partner
Trade DMRA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 18, 2026 · How we verify